Back to Search Start Over

Surveillance for sickle cell disease, United Republic of Tanzania.

Authors :
Ambrose EE
Smart LR
Charles M
Hernandez AG
Latham T
Hokororo A
Beyanga M
Howard TA
Kamugisha E
McElhinney KE
Tebuka E
Ware RE
Source :
Bulletin of the World Health Organization [Bull World Health Organ] 2020 Dec 01; Vol. 98 (12), pp. 859-868. Date of Electronic Publication: 2020 Sep 28.
Publication Year :
2020

Abstract

Objective: To determine the regional- and district-level newborn prevalence of sickle cell trait and disease, and the prevalence of haemoglobin variants and genetic modifiers of sickle cell disease, in the nine regions of north-western United Republic of Tanzania.<br />Methods: We repurposed dried blood spot samples from children (aged 0-24 months) born to mothers living with human immunodeficiency virus (HIV), collected as part of the HIV Early Infant Diagnosis programme, for sickle cell diagnosis. We performed isoelectric focusing to determine whether samples had normal haemoglobin, sickle cell trait, sickle cell disease or a rare haemoglobin variant. We shipped samples diagnosed as disease or variant to Cincinnati Children's Hospital in the United States of America for deoxyribonucleic-acid-based analyses to determine the prevalence of α-thalassaemia, glucose-6-phosphate dehydrogenase (G6PD) deficiency or fetal haemoglobin genetic modifiers.<br />Findings: We analysed a total of 17 200 specimens during February 2017-May 2018. We observed a prevalence of sickle cell trait and disease of 20.3% (3492/17 200) and 1.2% (210/17 200), respectively. District-level trait varied from 8.6% (5/58) to 28.1% (77/274). Among confirmed sickle cell disease specimens, we noted 42.7% (61/143) had 1-gene deletion and 14.7% (21/143) had 2-gene deletion α-thalassaemia trait. We documented G6PD A <superscript>-</superscript> deficiency in 19.2% (14/73) of males.<br />Conclusion: Our calculated prevalence is twice as high as previously reported and reinforces the need for enhanced sickle cell diagnostic services. Our district-level data will inform public health policy, allowing screening and disease-modifying hydroxyurea therapy to be focused on high-prevalence areas, until universal newborn screening is available.<br /> ((c) 2020 The authors; licensee World Health Organization.)

Details

Language :
English
ISSN :
1564-0604
Volume :
98
Issue :
12
Database :
MEDLINE
Journal :
Bulletin of the World Health Organization
Publication Type :
Academic Journal
Accession number :
33293746
Full Text :
https://doi.org/10.2471/BLT.20.253583